| Literature DB >> 27588184 |
Shigetaka Yagi1, Tamaki Yahata1, Yasushi Mabuchi1, Yuko Tanizaki1, Aya Kobayashi1, Michihisa Shiro1, Nami Ota1, Sawako Minami1, Masaki Terada2, Kazuhiko Ino1.
Abstract
The objective of the present study was to investigate the prognostic value of 18F-fluoro-2-deoxy-D-glucose (FDG) uptake by primary tumors on positron emission tomography/computed tomography (PET/CT) in surgically resectable cervical cancer. A total of 59 patients with stage IA2-IIB cervical cancer who underwent preoperative FDG-PET/CT, followed by radical hysterectomy and lymphadenectomy, were included in the study. The maximum standardized uptake value (SUVmax) of the primary tumor was measured, and the association between the SUVmax and clinicopathological factors or patient outcomes was analyzed. The SUVmax was significantly higher in patients with an advanced stage, lymph node metastasis, lymph-vascular space involvement and large tumors. The overall survival (OS) and progression-free survival (PFS) of patients with a high SUVmax were significantly lower compared with patients with a low SUVmax, using an optimal cut-off value of 7.36 for OS and 5.59 for PFS obtained from receiver operating characteristic curve analysis. Similarly, OS and PFS in patients with a high SUVmax were significantly lower in 39 patients with stage IB using a cut-off value of 7.90 and 6.69 for OS and PFS, respectively. Finally, multivariate analyses showed that the SUVmax of the primary tumor was an independent prognostic factor for impaired PFS in all patients and those with stage IB alone. These findings demonstrated that a high SUVmax on preoperative PET/CT was correlated with unfavorable clinical outcomes in patients receiving radical hysterectomy, suggesting that the SUVmax of the primary tumor may be a prognostic indicator for surgically-treated, early-stage invasive cervical cancer.Entities:
Keywords: cervical cancer; maximum standardized uptake value; positron emission tomography/computed tomography; prognosis; radical hysterectomy
Year: 2016 PMID: 27588184 PMCID: PMC4997975 DOI: 10.3892/mco.2016.953
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450